Sarepta Therapeutics, Inc. (LON:0L35)
London · Delayed Price · Currency is GBP · Price in USD 17.66
-0.43 (-2.36%)
At close: Sep 17, 2025
Sarepta Therapeutics Employees
Sarepta Therapeutics had 1,372 employees as of December 31, 2024. The number of employees increased by 58 or 4.41% compared to the previous year.
Employees
1,372
Change (1Y)
58
Growth (1Y)
4.41%
Revenue / Employee
1.32M GBP
Profits / Employee
-30.83K GBP
Market Cap
1.22B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1,372 | 58 | 4.41% |
| Dec 31, 2023 | 1,314 | 152 | 13.08% |
| Dec 31, 2022 | 1,162 | 322 | 38.33% |
| Dec 31, 2021 | 840 | -26 | -3.00% |
| Dec 31, 2020 | 866 | 123 | 16.55% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| AstraZeneca | 94,300 |
| GSK plc | 68,629 |
| Haleon | 24,561 |
| Smith & Nephew | 17,349 |
| ConvaTec Group | 10,489 |
| Hikma Pharmaceuticals | 9,500 |
| HUTCHMED (China) | 1,811 |
| Genus | 3,500 |
Sarepta Therapeutics News
- 19 days ago - SRPT Stock Alert: Investors with Large Losses Should Contact Robbins LLP for Information About the Pending Lead Plaintiff Deadline in the Sarepta Therapeutics, Inc. Class Action - GlobeNewsWire
- 21 days ago - mRNA Biotechs - Long-Term Value Risks Abound - Seeking Alpha
- 23 days ago - Investors in Sarepta Therapeutics, Inc. Should Contact Levi & Korsinsky Before August 25, 2025 to Discuss Your Rights – SRPT - GlobeNewsWire
- 23 days ago - SAREPTA FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Sarepta Therapeutics, Inc. and Encourages Investors to Contact the Firm Before the August 25th Deadline - GlobeNewsWire
- 23 days ago - FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics - Business Wire
- 23 days ago - INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - SRPT - GlobeNewsWire
- 24 days ago - Class Action Filed Against Sarepta Therapeutics, Inc. (SRPT) Seeking Recovery for Investors - Contact The Gross Law Firm - PRNewsWire
- 24 days ago - SRPT Shareholders Have the Right to Lead the Sarepta Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group Before the Final Deadline - SRPT - PRNewsWire